Catalyst Clinical Research announces that Nik Morton, the company’s president and COO, assumed its CEO role on 12 February 2024. Mr. Morton joined Catalyst as its COO in 2022. Mr. Morton moved into his new position while Nick Dyer, Catalyst’s former CEO, has shifted his focus to overseeing the strategic growth of the companies within Project Constellation Holdings, the parent company of Catalyst Clinical Research and Genpro Research.
“Nik is an experienced clinical research executive and is uniquely qualified to assume this role,” said Nick Dyer, Executive Chair for Project Constellation Holdings. “While working with Nik, I have seen a leader who values Catalyst and will build upon its industry-leading approaches while maintaining our caring and committed company culture.”
“We are excited to continue our work with Nik as he takes on this new role as CEO,” said QHP Capital Partners. “His previous position at Catalyst and the continued support from Nick Dyer as executive chair, ensures the strong continuity of focus for the Catalyst team, their clients and partners.”
“This is an amazing opportunity to guide Catalyst Clinical Research through its next period of growth and expand on its strengths,” Mr. Morton said. “My executive team and I will remain focused on delivering results for our clients and retaining the best employees in the clinical research industry.”
Prior to Mr. Morton joining Catalyst, he held strategic roles at PPD, including global leaderships roles for biostatistics, programming, medical writing, including functional services delivery; hematology and oncology project management overseeing full-service delivery; site and patient access—accountable for selecting the best sites for enrolling and for activating in the shortest cycle times; and the design and implementation of digitally enabled and decentralized clinical trials.
SOURCE : PRNewswire